Alemtuzumab‐resistant Sézary syndrome responding to zanolimumab*

Alexandroff, A.B.; Shpadaruk, Volha; Bamford, W. M.; Kennedy, Daniel B.; Burd, Robert M.; Dyer, Martin J. S.

doi:10.1111/j.1365-2141.2011.08620.x

Cited by 11 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lack of sustained response to treatment might be related to loss of CD52 expression, this has been recently reported in other pathologies (23,24). Recent studies might explain the incomplete effectiveness of alemtuzumab treatment through the prevalence of skin-tropic central memory T cells in the affected skin (25).…”

Section: Discussionmentioning

confidence: 93%

Alemtuzumab treatment for Sézary syndrome: A single-center experience

Novelli¹,

García-Muret

Sierra³

et al. 2015

Journal of Dermatological Treatment

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 93%

Alemtuzumab treatment for Sézary syndrome: A single-center experience

Novelli¹,

García-Muret

Sierra³

et al. 2015

Journal of Dermatological Treatment

View full text Add to dashboard Cite

show abstract

“…Zanolimumab (HuMax-CD4) is well tolerated and effective in CD4-positive PTCLs and SS and could therefore be considered for evaluation in the subset of CD4-positive PCSM-TCL, which relapse after local therapy. 66,67 On the other hand, none of these entities express CD30 and so would not be candidates for brentuximab vedotin (SGN-35), the antibody-drug conjugate being developed in CD30-positive Hodgkin lymphoma and NHL. 68,69 CONCLUSIONS In this era of increased awareness of the molecular and clinical heterogeneity of the NHLs, the rare non-MF, non-SS subtypes of CTCL are a case-in-point of the importance of precise diagnosis.…”

Section: Emerging Treatments For Peripheral T-cell Lymphomamentioning

confidence: 98%

Management of the Cutaneous Peripheral T-Cell Lymphomas

Choi

Lechowicz²

2012

The Cancer Journal

View full text Add to dashboard Cite

The cutaneous T-cell lymphomas are a heterogeneous collection of many biologically and clinically distinct cancers. The World Health Organization 2008 reclassification of cutaneous lymphomas delineated provisional entities that were previously classified simply as primary cutaneous peripheral T-cell lymphoma not otherwise specified. Because of the relative rarity of cases, standard treatment recommendations and algorithms are lacking. However, identification of these subtypes is important as they can have vastly different clinical outcomes. Furthermore, cytokine treatments effective in classic mycosis fungoides or Sezary syndrome not only are ineffective, but also may exacerbate certain subtypes. The aim of this review was to summarize the biological bases of the recently defined entities, reinforce the importance of acute clinical/pathologic diagnosis, and propose treatment strategies based on the available data.

show abstract

“…Die Ansprechrate in den vorliegenden Studien liegt bei etwa 56 % für therapierefraktäre MF. Bei einer Patientin mit therapierefraktärem SS, und fehlendem Ansprechen auf Alemtuzumab, konnte mit Zanolimumab nach vier Monaten eine nahezu komplette Remission erreicht werden . Nebenwirkungen traten in Form von Infekten und Dermatitiden auf .…”

Section: Systemtherapienunclassified

Neue und altbewährte Therapieoptionen bei Mycosis fungoides und Sézary‐Syndrom – eine aktuelle Bestandsaufnahme

Dugas-Breit

Schulze

Hallermann

2014

J Deutsche Derma Gesell

View full text Add to dashboard Cite

At the time of diagnosis primary cutaneous lymphomas are limited to the skin. T-cell lymphomas represent at least two thirds of all primary cutaneous lymphomas with mycosis fungoides and Sézary syndrome being the most frequent entities. A precise staging based on clinical, histological, immunohistological and molecular biological criteria is crucial for selecting the appropriate therapy. Since curative treatment is only possible in exceptional cases, the aim of any therapy is to achieve healing of the skin lesions, minimizing relapses, preventing progression and maintaining the quality of life. While in early disease stages skin-directed therapy is being used, in later stages systemic treatments become more important. This work aims to provide an overview of established and new therapies for the treatment of mycosis fungoides and Sézary syndrome.

show abstract

Alemtuzumab‐resistant Sézary syndrome responding to zanolimumab*

Cited by 11 publications

References 9 publications

Alemtuzumab treatment for Sézary syndrome: A single-center experience

Alemtuzumab treatment for Sézary syndrome: A single-center experience

Management of the Cutaneous Peripheral T-Cell Lymphomas

Neue und altbewährte Therapieoptionen bei Mycosis fungoides und Sézary‐Syndrom – eine aktuelle Bestandsaufnahme

Contact Info

Product

Resources

About